Citations

Clear

948 citation(s) found for "Li, Bryan".

From Priority Questions to Registry-Nested Trials: An AJRR-C Road Map for Advancing Arthroplasty Research
Hannon, Charles P , Springer, Bryan D. , Huddleston, James I , Kremers, Hilal Maradit , Lewallen, David G , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2106/jbjs.26.01407 | PMID 43050508 Get It

Background: The American Joint Replacement Research-Collaborative (AJRR-C) is a National Institutes of Health-funded P30 Core Center for Clinical Research and seeks to accelerate practice-changing arthroplasty research by leveraging the American Joint Replacement Registry (AJRR) and shared multicenter research infrastructure. The AJRR-C convened 2 complementary meetings to establish a scalable coordinated pathway from the identification of high-priority clinical questions to the initiation of prospective studies. Methods: In July 2025, leaders from The Hip Society, The Knee Society, the American Association of Hip and Knee Surgeons, the AJRR, the Orthopaedic Research and Education Foundation, and the broader research community identified and prioritized clinical research questions regarding infection, perioperative management, new technologies, surgical techniques, implants, and quality. In April 2026, orthopaedic surgeons, methodologists, and artificial intelligence experts reconvened to evaluate contemporary approaches for addressing these priorities. Results: A central theme of the meetings was the importance of utilizing a fit-for-purpose approach in which study design is tailored to the clinical question, available data, and potential sources of bias. Clinical questions with clear equipoise and feasible interventions may warrant randomization, whereas questions involving rare outcomes, rapidly evolving technologies, surgeon preferences, or long-term surveillance may be better addressed with observational studies. Participants emphasized the need for a robust, sustainable network for arthroplasty clinical trials that provides the shared infrastructure necessary for coordinated site engagement, standardized data definitions, reliable longitudinal follow-up, and AJRR linkage across multicenter trials. Two new AJRR-nested randomized trials arose from the priority-topics meeting, and their development demonstrates the potential of the AJRR-C consensus model to translate research priorities into practice-changing evidence generation. Conclusions: The AJRR-C established a coordinated pathway from the prioritization of research to the implementation of multicenter studies to address high-priority arthroplasty research questions. Sustaining this model requires continued collaboration among orthopaedic societies, investigators, methodologists, and the AJRR, as well as reliable funding mechanisms.
CYCLIC LOCAL ANTIBIOTIC IRRIGATION TO TREAT PERIPROSTHETIC JOINT INFECTION: 24-MONTH TREATMENT OUTCOMES FROM TWO PROSPECTIVE, RANDOMIZED TRIALS
Piuzzi, Nicolas, de Beaubien, Brian, Higuera, Carlos A. , Glassman, Andrew , Parvataneni, Hari , Urish, Kenneth L. , Springer, Bryan D.

Mayo Clinic

Orthopaedic Proceedings | November 6, 2026 | Volume: 108-B | Issue: SUPP_11 | Pages: 63-63

10.1302/1358-992x.2026.11.063 Get It

Introduction and Aim Periprosthetic joint infection (PJI) remains one of the most devastating complications following total joint arthroplasty, and a leading indication for revision surgery. As the incidence of PJI continues to rise, treatment outcomes remain constrained by sub-optimal standard-of-care treatment options. We conducted two prospective, randomized, multi-center, FDA-regulated clinical trials evaluating a novel PJI treatment* that uses cyclic, local, antibiotic irrigation to deliver high concentrations of vancomycin and tobramycin directly to the infected joint. Methods Patients with chronic hip or knee PJI were randomized to receive the CLEAR (cyclic, local, expedited, antibiotic-irrigation regimen) protocol with drug and device combination product* (CLEAR) or two-stage exchange arthroplasty (control) and followed for 24 months. CLEAR patients received 7 days of intra-articular cyclic irrigation with 80 mg tobramycin once daily, then hourly irrigation with 125 mg of vancomycin. The primary outcome was treatment success following explantation of the infected prosthesis, defined as infection control without suppressive antibiotics. Infection control included permanent prosthesis reimplantation, absence of reoperation, absence of PJI, and survival. Secondary outcomes included reimplantation rate, time to reimplantation, operative time, septic revision rate, and mortality. Results A total of 152 randomized patients underwent explantation [CLEAR: 76 patients; mean age: 67.0, 42.1% female, 89.5% White, mean BMI: 31.8, 56.6% knee; Control: 76 patients; mean age: 65.3, 32.9% female, 90.8% White, mean BMI: 34.0, 63.2% knee], of which 141 (93.0%) completed the 24-month assessment. At 24 months, 74.0% of patients (51/69) in the CLEAR group achieved treatment success compared to 51.4% in the control (37/72; significant nominal p=0.0058). Reimplantation rates were higher with the CLEAR protocol (100% vs. 87%), mean time to reimplantation was markedly shorter (7 vs. 127 days), and mean total operative time in the explant and reimplant surgeries was shorter (304 min vs 363 min). The control group experienced 83% more unplanned septic reoperations through 24 months (22 vs 12). The mortality rate at 24 months was higher in the control group (9.7% vs 7.2%). Conclusions The CLEAR protocol with the drug and device combination product* demonstrated superior outcomes at 24 months compared to two-stage exchange for chronic PJI. More patients treated using the CLEAR protocol with the drug and device combination product* received a permanent prosthesis, in a significantly shorter time, and more achieved treatment success, with shorter total operative time and fewer unplanned septic reoperations. These findings support the CLEAR protocol with the drug and device combination product* as a promising therapeutic strategy for the treatment of chronic PJI. * VT-X7 (Osteal Therapeutics)
IMPACT OF ORGANISM PROFILE ON IDEAL TIMING OF REIMPLANTATION IN PATIENTS UNDERGOING TWO-STAGE EXCHANGE ARTHROPLASTY
Tarabichi, Saad , Moore, Lane, Braithwaite, Collin , Verhey, Jens, Springer, Bryan, Wyles, Cody C. , Spangehl, Mark J. , Bingham, Joshua S.

Mayo Clinic

Orthopaedic Proceedings | November 6, 2026 | Volume: 108-B | Issue: SUPP_11 | Pages: 28-28

10.1302/1358-992x.2026.11.028 Get It

Introduction No study to date has examined the association between organism profile and ideal interstage duration in patients undergoing two-stage exchange arthroplasty. The purpose of this study was to evaluate the impact of the type of infecting organism on the optimal timing of reimplantation in this patient population. Methods This retrospective study identified 576 patients with chronic periprosthetic joint infection (PJI) of the knee that underwent two-stage exchange arthroplasty with a minimum 1-year follow-up. PJI was defined using the 2013 Musculoskeletal Infection Society (MSIS) criteria. Patients with a time to reimplantation >180 days from resection arthroplasty (n=76) and those that underwent spacer exchange were excluded (n=49). Treatment failure was defined as any reoperation for infection or PJI-related mortality. Receiver operator characteristic (ROC) curve analyses were used to identify whether the optimal interstage duration differed by infecting organism. Multivariate regression analyses were performed to identify risk factors for failure. Results 451 patients with a mean follow-up time of 5.8 ± 3.6 years were included. Of these, 71 (15.7%) patients experienced failure and 380 (84.3%) experienced success. ROC curve analyses demonstrated that the optimal interstage duration was longest for patients infected with “high-virulence” pathogens (129 days), followed by those with MSSA (117 days), culture negative PJI (98 days), and coagulase-negative Staphylococci (86 days). After controlling for co-variates, regression analyses showed that an interstage duration above the identified cutoff for each pathogen group was a predictor of treatment failure (all p<0.05). Conclusion We found that the ideal interstage duration varied considerably by the type of infecting organism in patients undergoing two-stage exchange. Greater awareness of this data may help guide the optimal timing of reimplantation in this patient population.
A Comparison of Two Strategies for Converting to Adalimumab Biosimilarsa
Erickson, Sara J, Rovey, Heather D H, Ramel, Cassandra L , Buechel, Bryan J, Swenson, Kelci A, Bartoo, Anna, Davis, John M.

Mayo Clinic

American Journal of Health-System Pharmacy | November 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajhp/zxag384 | PMID 42994452 Get It

Abstract Purpose We retrospectively compared 2 strategies for adalimumab biosimilar conversion at an academic medical center to better understand the effects of each strategy. Methods The formulary for our institution is managed by physician- and pharmacist-led task forces, in collaboration with our specialty pharmacy and pharmacy benefit manager. We implemented 2 phased strategies to increase adalimumab biosimilar utilization. First, we added preferred biosimilars to the formulary at parity to reference product and relied on prescribers to promote conversion. Second, we added an interchangeable biosimilar and removed reference product from the formulary while leveraging specialty pharmacy workflows for prescription conversions, streamlined facility inventory, and minimized dependence on prescriber workflows. For both strategies, we evaluated prescribing trends, dispensing data, and pharmaceutical spend for all medical center patients, specialty pharmacy patients, and patients with the top 3 specialty pharmacy payers. Results During phase 1 (quarter [Q] 2 of 2023 [2Q23] to 1Q24), reference product dispensing remained largely unchanged (&lt;5% reduction). Phase 2 (2Q24 to 2Q25) resulted in a significant reduction in specialty pharmacy dispenses of reference product, from 95.7% to 19.0%. This phase also resulted in a 76.0% reduction in medical center adalimumab/biosimilar spend. At the end of phase 2, biosimilar accounted for 42.6% of all medical center patient prescriptions. Total dispensed units of reference product/biosimilar were modestly decreased (6%) during phase 2. Conclusion Formulary and clinical support for adalimumab biosimilar alone did not promote use over the reference product, but rapid and substantial biosimilar uptake was achieved after operational barriers were addressed.
Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
Greenall, Sam A , Chen, Shengnan C , Alton, Gordon , Beaton, Graham , Casey, Mattie , Babic, Ivan , Tucci, Fabio C , Ravula, Satheesh B , Stein, Gregory D , Li, Yuchen , D'Souza, Rochelle , Kumar, Ashwani , Kittler, Ralf , Tuma, Ann C M, Sarkaria, Jann N , Gough, Daniel J , Stewart, Rodney A , Kesari, Santosh , Day, Bryan W , Johns, Terrance G

Mayo Clinic

No container title available | October 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.10.14.759257 | PMID 42995774 Get It

Background: Glioblastoma (GBM) remains uniformly fatal. The basic helix-loop-helix transcription factor OLIG2 is universally expressed in diffuse glioma, sustains the tumor-propagating stem-like fraction, and opposes p53-mediated genotoxic responses, but has historically been considered undruggable. We characterized CT-179, a brain-penetrant small-molecule OLIG2 inhibitor, as a candidate therapeutic for GBM. Methods: Target engagement was assessed by cellular thermal shift assay, differential scanning fluorimetry, crosslinking, and electrophoretic mobility shift assay. Anti-tumor activity was evaluated across eleven patient-derived GBM cell lines, in zebrafish oligodendrocyte precursor cell (OPC)-derived tumors, and orthotopic and subcutaneous GBM models, including combinations with radiotherapy plus temozolomide and with selective Bcl-2 family inhibitors. Results: CT-179 engaged OLIG2 and altered the conformation of dimerized OLIG2 on chromatin without preventing dimerization or fully displacing OLIG2 from DNA. CT-179 reduced OLIG2-positive OPCs and OPC-derived tumors in zebrafish and inhibited proliferation across all eleven GBM lines (IC50 < 360 nM), depleting the stem-like fraction and inducing apoptosis through mitotic catastrophe, mitotic slippage, or a hybrid response. RNA-seq across three patient-derived glioma stem cell lines identified β-tubulin gene isoforms as the most strongly CT-179-down-regulated transcripts at the early time point and showed correlated β-tubulin and OLIG2 expression in TCGA glioblastoma specimens. Combination with the Mcl-1 inhibitor S63845 or the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 produced greater-than-additive cytotoxicity. Oral CT-179 crossed the blood-brain barrier and extended median survival as a single agent across two independent adult orthotopic patient-derived backgrounds (GBM8 and G06); intraperitoneal CT-179 was associated with reduced intratumoral OLIG2 and Ki-67 staining in GBM8 orthotopic xenografts. Combination of CT-179 with radiotherapy and temozolomide eliminated all GBM8 and 7 of 8 GBM4 subcutaneous xenografts without weight loss and significantly extended survival when combined with radiotherapy in MGMT-unmethylated GBM6 orthotopic xenografts (CT-179 administered intraperitoneally). Conclusions: CT-179 is a brain-penetrant inhibitor of an established GBM driver with single-agent and combination activity across several orthotopic models, supporting clinical development for GBM and translational evaluation in other OLIG2-dependent CNS malignancies.
Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Paolillo, Emily W. , Dhanam, Sreya , Taylor, Jack C. , Sanderson-Cimino, Mark, Fregly, Ray, Saloner, Rowan, Casaletto, Kaitlin B, Kramer, Joel H, Miller, Bruce L, Seeley, William W, Gorno-Tempini, Maria Luisa, Ljubenkov, Peter A. , Rojas, Julio C, Lee, Suzee, Sturm, Virginia, Appleby, Brian, Bayram, Ece, Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S, Vito, Alyssa , Eldaief, Mark, Fields, Julie A. , Ghoshal, Nupur , Huey, Edward D, Irwin, David J, Kantarci, Kejal, Kwan, Justin , Mackenzie, Ian R. , Masdeu, Joseph C, Onyike, Chiadi U, Pantelyat, Alexander, Pascual, Belén , Popli, Tanav, Rascovsky, Katya, Rezaii, Neguine , Scholz, Sonja W. , Snyder, Allison , Tartaglia, Maria Carmela , Traynor, Bryan J, Wong, Bonnie, Kornak, John , Kremers, Walter K. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley F. , Rosen, Howard J, Boxer, Adam L, Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Saloner, Rowan , Casaletto, Kaitlin B. , Kramer, Joel H. , Miller, Bruce L. , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Rojas, Julio C. , Sturm, Virginia E. , Appleby, Brian S. , Day, Gregory S, Vito, Alyssa De, Eldaief, Mark C. , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Masdeu, Joseph, Onyike, Chiadi U. , Popli, Tanav A. , Tartaglia, Maria Carmela , Traynor, Bryan J. , Rosen, Howard J. , Boxer, Adam L.

Mayo Clinic

No container title available | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.26363439 | PMID 42818136 Get It

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility of passive smartphone monitoring in FTLD using a multi-domain mobile assessment platform. Methods: Participants were 567 adults (53% clinically normal, 21% prodromal FTLD, 26% symptomatic FTLD) who completed an in-person study visit and downloaded the ALLFTD Mobile App on their personal smartphones. The app delivered unsupervised cognitive tests and passively collected continuous data on battery percentage (proxy for smartphone use) and step count. Longitudinal follow-up included smartphone monitoring and annual in-person study visits. Primary analyses examined associations between passive smartphone features and markers of disease severity at baseline and longitudinally, and tested whether passive features added incremental value beyond app-based cognitive testing. Results: Passive smartphone features were feasible to collect and showed excellent reliability with <2 weeks of monitoring (ICCs>0.9). Features capturing smartphone use and movement demonstrated sensitivity to gold-standard clinical measures of disease severity both at baseline and longitudinally. A classification model combining passive features, the app-based cognitive composite score, and demographics detected longitudinal functional decline (AUC=0.89); passive features alone (AUC=0.84) performed comparably to a cognitive screener (AUC=0.85). Discussion: Passive smartphone monitoring is a valid, zero-burden measure of disease severity and progression in FTLD that adds modest incremental value beyond app-based cognitive testing. Findings support its use as a scalable digital endpoint in longitudinal FTLD research.
Analysis of Complications Associated with Basivertebral Nerve Ablation for Vertebrogenic Low Back Pain: A Multicenter Retrospective Cohort Study of 1,145 Patients
Hoelzer, Bryan C. , Obray, Acelan, Naidu, Ramana, Cooper, Amanda , McCormick, Zachary L, Kanjanapanang, Napatpaphan , Moore, Greg, Her, Yeng F , Pittelkow, Thomas P. , Olatoye, Oludare, Freeman, Eric, Parker, Mikayla, Mitchell, Ellie A, Peterson, Lucas, Childs, Bryson, Eckstrom, Erik, Ekstrom, Petra V, Haugen, Lindsey A, Hamann, Ashley L, Carson, Grace G, Mayeri, Alyssa S, Peterson, Candance M, Fortin, Hayden E, Cooper, Amanda

Mayo Clinic

Pain Medicine | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/pm/pnag122 | PMID 42765343 Get It

Abstract Objective Low back pain (LBP) is a leading cause of pain and disability worldwide. Recent studies demonstrate a vertebrogenic model involving the basivertebral nerve (BVN) as a cause of chronic LBP. Vertebral endplates are highly innervated by the BVN, and literature shows type 1 and 2 Modic changes at vertebral endplates are a source of vertebrogenic low back pain (VBP). As a result, intraosseous radiofrequency ablation of the BVN is a minimally invasive outpatient procedure used to treat VBP. We conducted a retrospective review of 1,145 patients that have undergone BVN ablation to assess for safety and complication management. Methods Chart reviews were conducted to obtain demographic and pre-procedural information regarding patient gender, age at the time of BVN ablation, duration of LBP, and BMI. Post-procedure information derived from chart notes included vertebral levels ablated and post-BVN ablation complications, which were categorized as increased LBP &gt; 7 days, increased radicular pain &gt; 7 days, lower extremity weakness, infection, vertebral compression fracture, superficial bleeding, spinal or epidural hematoma, serious neurological injury, visit to the ER, and deep vein thrombosis/clot. Results 1,145 patient charts were reviewed showing an overall complication rate of 3.2% (37 complications). Increased radicular pain was the most common complication at 2.2% (25 complications) and resolved completely in all but one patient. The overall complication rate fell to 1.1% (13 complications) when the 24 cases of transient radicular pain were not counted as adverse events. Conclusions In this multicenter retrospective review, the overall rate of complications related to BVN ablation was low (3.2%). The most common complication was temporary radicular pain that resolved with conservative care. These findings suggest that BVN ablation is a safe treatment for VBP in real-world clinical settings.
Acute Coronary Event - Return To Exercise Approach
Tayon, Kevin G. , Gutzwiller, Leah, Carlisle, Ashley E., Dineen, Elizabeth, Ali, Mays, Shapiro, Brian, Taylor, Bryan, Shapiro, Brian

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001260200.84050.cc Get It

Longitudinal Analysis Of Cardiopulmonary Fitness During Covid-19: An Era-Based Study (2017-2024)
Gutzwiller, Leah, Ala, Ronith, Carlisle, Ashley, Tayon, Kevin, Miller, Kali, Dineen, Elizabeth, Shapiro, Brian, Shapiro, Bryan , Carlisle, Ashley E., Tayon, Kevin

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001265020.60075.d3 Get It

Measured Versus Predicted Maximum Heart Rate During CPET: Agreement And Contributors To Error
Tayon, Kevin G. , Carlisle, Ashley E., Tawk, Rhoda, Gutzwiller, Leah, Shapiro, Brian, Taylor, Bryan, Dineen, Elizabeth H. , Shapiro, Brian

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001258792.44810.69 Get It